15959-39-4Relevant articles and documents
Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics
Pal, Krishnendu,Pore, Subratakumar,Sinha, Sutapa,Janardhanan, Rajiv,Mukhopadhyay, Debabrata,Banerjee, Rajkumar
experimental part, p. 2378 - 2390 (2011/06/11)
Haloperidol (HP), a neuroleptic drug, shows high affinity toward-receptors (SR). HP and reduced-HP at higher concentration were known to induce apoptosis in SR-overexpressing carcinomas and melanomas. Herein, we report the development of cationic lipid-conjugated haloperidol as a new class of anticancer therapeutics. In comparison to HP, the C-8 carbon chain analogue (HP-C8) showed significantly high, SR-assisted antiproliferative activity against cancer cells via caspase-3-mediated apoptosis and down-regulation of pAkt. Moreover, melanoma tumor aggressiveness in HP-C8-treated mice was significantly lower than that in HP-treated mice. HP-C8 simultaneously reduced Akt-protein level and increased Bax/Bcl-2 ratio in vascular endothelial cells, thereby indicating a possible protein kinase down-regulatory and apoptosis inducing role in tumor-associated vascular cells. In conclusion, we developed-receptor-targeting cationic lipid-modified HP derivatives as a promising class of anticancer therapeutic that concurrently affects cancer and tumor environment associated angiogenic vascular cells through induction of apoptosis and Akt protein down-regulation.
